ペプチドおよびオリゴヌクレオチドCDMOの世界市場

ペプチドおよびオリゴヌクレオチドCDMOの世界市場は2030年までに57億米ドルに到達

2024年に28億米ドルと推定されるペプチドおよびオリゴヌクレオチドCDMOの世界市場は、分析期間2024-2030年にCAGR 12.8%で成長し、2030年には57億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるペプチドは、CAGR 14.1%を記録し、分析期間終了までに42億米ドルに達すると予測されています。オリゴヌクレオチド分野の成長率は、分析期間中CAGR 9.4%と推定されます。

米国市場は7億5,230万米ドルと推定、中国はCAGR17.3%で成長すると予測

米国のペプチドおよびオリゴヌクレオチドCDMO市場は、2024年に7億5,230万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは17.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.2％と11.4％と予測されています。欧州では、ドイツがCAGR 10.1%で成長すると予測されています。

世界のペプチドおよびオリゴヌクレオチドCDMO市場- 主要動向と促進要因まとめ

ペプチドおよびオリゴヌクレオチドCDMOとは何か？

ペプチド・オリゴヌクレオチド開発製造受託機関（CDMO）は、ペプチドとオリゴヌクレオチドの開発と製造を専門としています。これらのバイオ医薬品は、がん、自己免疫疾患、遺伝性疾患、ウイルス感染症など、さまざまな疾患の治療薬開発に欠かせないです。ペプチドおよびオリゴヌクレオチドCDMOの役割は、これらの複雑な分子の研究、開発、大量生産に関するサービスを提供することです。これらのサービスには通常、創薬、プロセス開発、製造、商品化サポートが含まれ、製品が製薬業界の厳しい規制要件を満たすことを保証します。

ペプチド医薬品は、従来の低分子医薬品に比べて特異性が高く毒性が低いため、大きな支持を集めています。オリゴヌクレオチドは、RNAベースの治療薬やアンチセンス・オリゴヌクレオチドのような製品を含み、遺伝子発現を標的にして調節する能力から、ますます重要になってきています。ペプチドやオリゴヌクレオチドに特化したCDMOは、製薬会社がこれらの高度に専門化した分子を製造する際の課題を克服する手助けをします。これには、スケーラビリティ、純度、収率の最適化、規制遵守の確保などに関する課題の克服が含まれます。ペプチドやオリゴヌクレオチドをベースとする医薬品の市場が拡大し続ける中、この分野におけるCDMOサービスの需要は大幅に増加する見込みです。

なぜペプチドおよびオリゴヌクレオチドCDMO市場は拡大しているのか？

ペプチドおよびオリゴヌクレオチドCDMO市場は、生物製剤や個別化医療の台頭、RNA治療の進歩、慢性疾患の有病率の増加など、いくつかの重要な要因によって拡大しています。最も顕著な促進要因の1つは、生物学的製剤、特にペプチドやオリゴヌクレオチドへのシフトが進んでいることです。これらの生物学的製剤は、特異性が高く、副作用が少なく、希少な遺伝性疾患、特定のがん、ウイルス感染症など、以前は管理が困難であった疾患の治療に用いることができます。

RNAベースの治療法の進歩も、ペプチドおよびオリゴヌクレオチドCDMO市場の成長に寄与する主要因の一つです。COVID-19パンデミックに対するmRNAワクチンの成功は、医療におけるRNA技術の可能性を浮き彫りにしました。その結果、オリゴヌクレオチド製造サービスに対する需要は、特にmRNAワクチン、遺伝子編集ツール、RNA干渉療法などの製品に対して急速に高まっています。製薬会社やバイオテクノロジー企業は、このような複雑な分子の製造・開発に精通したCDMOパートナーを求めるようになっています。小分子干渉RNA（siRNA）、メッセンジャーRNA（mRNA）、アンチセンスオリゴヌクレオチド（ASO）を含むオリゴヌクレオチドに対する需要は、RNA治療薬の研究が拡大するにつれて上昇基調を続けると予想されます。

加えて、がん、糖尿病、心血管疾患などの慢性疾患の有病率の増加が、ペプチドやオリゴヌクレオチドを含む新規治療アプローチの必要性を高めています。世界人口の高齢化に伴い、これらの疾患の根本的な原因を分子レベルで標的とする革新的な医薬品に対する需要が高まっています。このため、臨床段階や商業段階に入るペプチドやオリゴヌクレオチドベースの医薬品候補の数が増え、CDMOが提供する専門的な製造・開発サービスへの需要がさらに高まっています。

ペプチド・オリゴヌクレオチドCDMOの将来を形作る主要動向とは？

ペプチドおよびオリゴヌクレオチドCDMO市場の将来は、製造技術の進歩、品質と規制遵守の重要性の高まり、拡張性と柔軟性への注目の高まりなど、いくつかの変革的動向によって形作られています。重要な動向のひとつは、ペプチドとオリゴヌクレオチドの合成技術の進歩であり、より迅速で効率的、かつコスト効率の高い製造工程を可能にしています。固相ペプチド合成（SPPS）、連続フローケミストリー、自動化ハイスループットシステムなどの技術革新により、高品質のペプチドやオリゴヌクレオチドを大規模に生産する能力が向上しており、これは世界の需要の増加に対応するために不可欠です。

さらに、ペプチドやオリゴヌクレオチドを含む生物製剤の規制環境はより厳しくなっており、CDMOが品質管理対策を強化し、世界の規制へのコンプライアンスを確保する必要性が高まっています。これには、米国FDAや欧州医薬品庁（EMA）のような、生物製剤の開発・製造・流通に厳格なガイドラインを持つ規制機関が定める要件を満たすことも含まれます。生物製剤の複雑さが増すにつれて、CDMOは進化する規制基準を先取りし、製造工程が完全に準拠し、最高レベルの純度と有効性を持つ治療薬を製造できるようにベストプラクティスを採用する必要があります。

もう一つの重要な動向は、柔軟でスケーラブルな製造ソリューションに対する需要の高まりです。ペプチドやオリゴヌクレオチドをベースとした治療薬が臨床パイプラインを進むにつれて、医薬品開発企業は、医薬品開発の進行に合わせて拡張できる柔軟な製造能力を提供できるCDMOを必要としています。この柔軟性は、製薬会社が費用対効果、品質、規制遵守を維持しながら効率的に生産規模を拡大できるようにするために不可欠です。個別化医療や標的治療が一般的になるにつれ、CDMOは個々の医薬品候補のユニークなニーズに応えることができるカスタマイズされたソリューションを提供する適応力も必要となるでしょう。

ペプチドおよびオリゴヌクレオチドCDMO市場の成長促進要因は？

ペプチドおよびオリゴヌクレオチドCDMO市場の成長は、生物製剤の需要増加、RNAベースの治療法の進歩、遺伝子を標的とした治療に関する研究の活発化など、いくつかの要因によってもたらされます。製薬業界が生物学的製剤へのシフトを続ける中、ペプチドやオリゴヌクレオチドは、より高い精度と少ない副作用で特定の生物学的プロセスを標的にする能力があるため、大きな注目を集めています。このため、これらの治療法に焦点を当てた研究開発活動が急増し、その結果、これらの分子の製造とスケールアップの専門知識を提供できる専門CDMOサービスの需要が高まっています。

RNAベースの治療法、特にmRNAワクチンと遺伝子治療の急速な開発と承認が、CDMOセクターの成長をさらに加速させています。COVID-19のmRNAワクチンの成功に続き、より幅広い疾患の治療にRNA技術の応用を拡大することへの関心が高まっています。このため、オリゴヌクレオチド合成とRNA生産において高度な能力を持つCDMOへのニーズが高まっています。RNAベースの治療薬のパイプラインが成長するにつれて、オリゴヌクレオチド製造に特化したCDMOは、臨床試験や商業的発売に向けて生産を拡大する製薬会社をサポートするのに有利な立場にあります。

さらに、個別化医療への注目が高まるにつれ、より専門的で小規模、高品質のペプチドやオリゴヌクレオチド製造サービスへのニーズが高まっています。特定の遺伝子マーカーや疾患サブタイプを標的とする医薬品の開発が進むにつれて、高い品質を維持しながら、小規模でカスタマイズされたバッチに対応できる精密製造が重視されるようになっています。柔軟性があり、スケーラブルで高品質な製造能力を提供するCDMOは、こうした技術革新をサポートするためにますます需要が高まっています。さらに、慢性疾患の蔓延と遺伝子編集療法へのシフトが、ペプチドおよびオリゴヌクレオチドCDMO市場の拡大に寄与しています。

セグメント

製品タイプ（ペプチド、オリゴヌクレオチド）;サービスタイプ（受託製造サービス、受託開発サービス）;エンドユーザー（製薬企業エンドユーザー、バイオ医薬品企業エンドユーザー、その他エンドユーザー）

調査対象企業の例

• Agilent Technologies, Inc.
• Ajinomoto Co., Inc.
• Almac Group
• Aurigene Pharmaceutical Services Ltd.
• Bachem Holding AG
• BioSynthesis Inc.
• Catalent, Inc.
• CordenPharma International
• EUROAPI
• GenScript Biotech Corporation
• Kaneka Eurogentec S.A.
• Lonza Group AG
• Merck KGaA
• Piramal Pharma Solutions
• PolyPeptide Group
• Rentschler Biopharma SE
• Senn Chemicals AG
• STA Pharmaceutical Co., Ltd.（WuXi STA）
• Thermo Fisher Scientific Inc.
• Wuxi AppTec Co., Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Peptide and Oligonucleotide CDMO Market to Reach US$5.7 Billion by 2030

The global market for Peptide and Oligonucleotide CDMO estimated at US$2.8 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. Peptides, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Oligonucleotides segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$752.3 Million While China is Forecast to Grow at 17.3% CAGR

The Peptide and Oligonucleotide CDMO market in the U.S. is estimated at US$752.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Peptide and Oligonucleotide CDMO Market - Key Trends & Drivers Summarized

What Is a Peptide and Oligonucleotide CDMO and How Does It Work?

A Peptide and Oligonucleotide Contract Development and Manufacturing Organization (CDMO) specializes in the development and manufacturing of peptides and oligonucleotides, which are short chains of amino acids and nucleotides, respectively. These biopharmaceutical products are crucial in the development of therapeutics for a range of diseases, including cancer, autoimmune disorders, genetic diseases, and viral infections. The role of a peptide and oligonucleotide CDMO is to provide services related to the research, development, and large-scale production of these complex molecules. These services typically include drug discovery, process development, manufacturing, and commercialization support, ensuring that the products meet the stringent regulatory requirements of the pharmaceutical industry.

Peptide drugs are gaining significant traction due to their specificity and lower toxicity compared to traditional small-molecule drugs. Oligonucleotides, which include products like RNA-based therapeutics and antisense oligonucleotides, are becoming increasingly important for their ability to target and modulate gene expression. CDMOs focused on peptides and oligonucleotides help pharmaceutical companies navigate the challenges of producing these highly specialized molecules. This includes overcoming challenges related to scalability, purity, yield optimization, and ensuring regulatory compliance. As the market for peptide and oligonucleotide-based drugs continues to expand, the demand for CDMO services in this space is poised to increase substantially.

Why Is the Peptide and Oligonucleotide CDMO Market Expanding?

The peptide and oligonucleotide CDMO market is growing due to several key factors, including the rise of biologics and personalized medicine, advances in RNA therapies, and the increasing prevalence of chronic diseases. One of the most prominent drivers is the growing shift toward biologic drugs, particularly peptides and oligonucleotides, which are considered more targeted and precise compared to traditional small-molecule drugs. These biologics offer higher specificity, fewer side effects, and can be used to treat diseases that were previously challenging to manage, such as rare genetic disorders, certain cancers, and viral infections.

The advancement of RNA-based therapies is another major factor contributing to the growth of the peptide and oligonucleotide CDMO market. The success of mRNA vaccines in combating the COVID-19 pandemic has highlighted the potential of RNA technologies in medicine. As a result, the demand for oligonucleotide manufacturing services is rapidly increasing, particularly for products like mRNA vaccines, gene-editing tools, and RNA interference therapies. Pharmaceutical companies and biotech firms are increasingly seeking CDMO partners with expertise in the production and development of these complex molecules. The demand for oligonucleotides, including small interfering RNA (siRNA), messenger RNA (mRNA), and antisense oligonucleotides (ASOs), is expected to continue its upward trajectory as research into RNA therapeutics expands.

In addition, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is driving the need for novel therapeutic approaches, including those involving peptides and oligonucleotides. As the global population ages, there is an escalating demand for innovative drugs that target the underlying causes of these diseases at a molecular level. This has led to a growing number of peptide and oligonucleotide-based drug candidates entering the clinical and commercial stages, further increasing the demand for specialized manufacturing and development services offered by CDMOs.

What Key Trends Are Shaping the Future of Peptide and Oligonucleotide CDMOs?

The future of the peptide and oligonucleotide CDMO market is being shaped by several transformative trends, including advances in manufacturing technologies, the increasing importance of quality and regulatory compliance, and the growing focus on scalability and flexibility. One key trend is the advancement of peptide and oligonucleotide synthesis technologies, which are enabling faster, more efficient, and cost-effective manufacturing processes. Innovations in solid-phase peptide synthesis (SPPS), continuous-flow chemistry, and automated high-throughput systems are improving the ability to produce high-quality peptides and oligonucleotides at scale, which is critical for meeting the increasing global demand.

Additionally, the regulatory environment for biologics, including peptides and oligonucleotides, is becoming more stringent, driving the need for CDMOs to enhance their quality control measures and ensure compliance with global regulations. This includes meeting the requirements set by regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA), which have strict guidelines for the development, manufacturing, and distribution of biologics. As the complexity of biologics increases, CDMOs will need to stay ahead of evolving regulatory standards and adopt best practices to ensure that their manufacturing processes are fully compliant and capable of producing therapeutics with the highest levels of purity and efficacy.

Another important trend is the growing demand for flexible and scalable manufacturing solutions. As peptide and oligonucleotide-based therapeutics move through the clinical pipeline, drug developers require CDMOs that can provide flexible manufacturing capabilities that scale with the progression of the drug’s development. This flexibility is essential as it allows pharmaceutical companies to efficiently scale up production while maintaining cost-effectiveness, quality, and regulatory compliance. As personalized medicine and targeted therapies become more common, CDMOs will also need to be adaptable in offering customized solutions that can cater to the unique needs of individual drug candidates.

What Are the Key Drivers of Growth in the Peptide and Oligonucleotide CDMO Market?

The growth in the peptide and oligonucleotide CDMO market is driven by several factors, including increasing demand for biologics, advancements in RNA-based therapies, and growing research into gene-targeted treatments. As the pharmaceutical industry continues to shift toward biologic drugs, peptides and oligonucleotides have gained significant attention due to their ability to target specific biological processes with higher precision and fewer side effects. This has led to a surge in research and development activities focused on these therapeutic modalities, thereby increasing the demand for specialized CDMO services that can provide expertise in the manufacturing and scale-up of these molecules.

The rapid development and approval of RNA-based therapies, especially mRNA vaccines and gene therapies, have further fueled growth in the CDMO sector. Following the success of mRNA vaccines for COVID-19, there has been a heightened interest in expanding the application of RNA technologies to treat a broader range of diseases. This has driven the need for CDMOs with advanced capabilities in oligonucleotide synthesis and RNA production. As the pipeline for RNA-based therapeutics grows, CDMOs that specialize in oligonucleotide manufacturing are well-positioned to support pharmaceutical companies as they scale up production for clinical trials and commercial launch.

Additionally, the increasing focus on personalized medicine is driving the need for more specialized, small-scale, high-quality peptide and oligonucleotide manufacturing services. As more drugs are developed to target specific genetic markers or disease subtypes, there is a greater emphasis on precision manufacturing that can accommodate smaller, customized batches while maintaining high levels of quality. CDMOs that offer flexible, scalable, and high-quality production capabilities are increasingly in demand to support these innovations. Moreover, the growing prevalence of chronic diseases and the shift toward gene-editing therapies are contributing to the expansion of the peptide and oligonucleotide CDMO market, as these technologies offer new avenues for treating previously untreatable conditions.

SCOPE OF STUDY:

The report analyzes the Peptide and Oligonucleotide CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Peptides, Oligonucleotides); Service Type (Contract Manufacturing Service, Contract Development Service); End-Use (Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Agilent Technologies, Inc.
• Ajinomoto Co., Inc.
• Almac Group
• Aurigene Pharmaceutical Services Ltd.
• Bachem Holding AG
• BioSynthesis Inc.
• Catalent, Inc.
• CordenPharma International
• EUROAPI
• GenScript Biotech Corporation
• Kaneka Eurogentec S.A.
• Lonza Group AG
• Merck KGaA
• Piramal Pharma Solutions
• PolyPeptide Group
• Rentschler Biopharma SE
• Senn Chemicals AG
• STA Pharmaceutical Co., Ltd. (WuXi STA)
• Thermo Fisher Scientific Inc.
• Wuxi AppTec Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Peptide and Oligonucleotide CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Targeted Therapies Propels Growth of Peptide and Oligonucleotide CDMO Services
  • Surging Investments in mRNA and RNAi Technologies Expands Addressable Market Opportunity for Oligonucleotide CDMOs
  • Advancements in Solid-Phase Peptide Synthesis (SPPS) Strengthen Business Case for Outsourcing Complex Peptides
  • Biopharma Industry's Shift Toward Outsourcing Accelerates Demand for End-to-End CDMO Partnerships
  • Expanding Applications of Peptides in Metabolic and Oncology Therapies Drives Market Penetration
  • Regulatory Encouragement for Orphan and Rare Disease Drugs Throws the Spotlight on Oligonucleotide-Based Therapies
  • Growing Pipeline of Nucleic Acid Therapeutics Spurs Long-Term CDMO Opportunities
  • Increasing Complexity of Molecule Design Generates Demand for Specialized CDMO Capabilities
  • Personalized Medicine Trends Drive Adoption of Custom Peptide and Oligo Synthesis Services
  • Emergence of Cell and Gene Therapies Expands Synergistic Opportunities for Nucleic Acid CDMOs
  • Emergence of Next-Generation Sequencing (NGS) Tools Strengthens Market for Oligonucleotide-Enabled Diagnostics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Peptide and Oligonucleotide CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Contract Manufacturing Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Contract Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Biopharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 101: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 119: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Russia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 149: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Australia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 158: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: India Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 161: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 167: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 185: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 197: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 215: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 233: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 234: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 245: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Iran Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 272: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: UAE Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Peptide and Oligonucleotide CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 290: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Africa Historic Review for Peptide and Oligonucleotide CDMO by Product Type - Peptides and Oligonucleotides Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Product Type - Percentage Breakdown of Value Sales for Peptides and Oligonucleotides for the Years 2015, 2025 & 2030
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Peptide and Oligonucleotide CDMO by Service Type - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Peptide and Oligonucleotide CDMO by End-Use - Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Peptide and Oligonucleotide CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION